StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note released on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 1.1 %

NASDAQ LPCN opened at $3.19 on Wednesday. The stock has a market cap of $17.03 million, a PE ratio of -4.19 and a beta of 1.23. Lipocine has a fifty-two week low of $2.96 and a fifty-two week high of $11.79. The business has a 50 day moving average price of $4.36 and a two-hundred day moving average price of $4.58.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC boosted its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.